Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Neuroimaging & Brain Measures

Mescaline for Neuroimaging & Brain Measures

7 papers and 2 clinical trials exploring mescaline as a treatment for neuroimaging & brain measures.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationApproximately 264 million people globally suffer from depression, with PTSD affecting around 8 million adults in the United States each year.

Neuroimaging & Brain Measures

Recent advances in neuroimaging have shed light on the neurobiological mechanisms underlying the effects of psychedelics, particularly in the treatment of mental health disorders such as depression and PTSD. Studies involving compounds like psilocybin and MDMA have demonstrated significant changes in brain activity associated with therapeutic outcomes.

Full Neuroimaging & Brain Measures profile

Academic Research

7 papers
Paywallmeta

Mescaline: The forgotten psychedelic

This review (2022) explores mescaline's pharmacological and behavioural effects using preclinical and clinical research. The pharmacological mechanisms of mescaline are similar to those of other classical psychedelics i.e. binding at the 5HT2A receptor. Mescaline can improve well-being and mental health conditions, particularly alcohol use disorder.

Published
October 14, 2022
Journal
Neuropharmacology
Authors
Narine, K., Campbell, I., Dyck, J., Nutt, D. J., Vamvakopulou, I. A.
Open Accessmeta

Sustained effects of single doses of classical psychedelics in humans

This review (2022) explores the acute effects of classic psychedelics in clinical research with humans and summarizes behavioural, biochemical, neuroimaging and electrophysiological data in order to support the notion that the intriguing effects of psychedelics on the human brain and mind are based on neural plasticity.

Published
June 21, 2022
Journal
Neuropsychopharmacology
Authors
Knudsen, G. M.
Paywallindividual

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

This animal study assesses the effects of tryptamine and phenethylamine psychedelics (psilocin, LSD, mescaline and dimethoxybromoamphetamine (DOB)) using EEG in freely moving rats. The researchers found that all psychedelic's caused a global decrease in EEG activity. The overall results were almost identical to the effects from human EEG studies, proving that the method has robust translational validity.

Published
October 2, 2021
Journal
Translational Psychiatry
Authors
Vejmola, Č., Tylš, F., Piorecká, V., Koudelka, V., Kadeřábek, L., Novák, T., Páleníček, T.
Open Accessmeta

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

This review summarises preclinical and clinical evidence that ketamine, psilocybin, LSD and MDMA have therapeutic potential for psychiatric disorders — with robust support for ketamine in depression, emerging evidence for psilocybin and LSD in treating depression and modulating functional brain connectivity, and MDMA showing efficacy in PTSD. It also delineates the pharmacology and behavioural effects of psychedelic versus non‑psychedelic hallucinogens and entactogens.

Published
November 30, 2020
Journal
Journal of Neuroscience
Authors
Hibicke, M., Gobbi, G.
Paywallmeta

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

This comprehensive review (2019) by some of the leading researchers in psychedelics looks at both the epidemiological & clinical studies and the positive (and negative) effect that psychedelics can have.

Published
May 1, 2019
Journal
Pharmacology and Therapeutics
Authors
Johnson, M. W., Hendricks, P. S., Barrett, F. S., Griffiths, R. R.
Paywallmeta

Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging

This systematic review (2016; s=25) analyzed neuroimaging data regarding the effects of serotonergic psychedelics, including ayahuasca, psilocybin, and LSD. The study finds that these substances generally inhibit the default mode network and modulate fronto-temporo-parieto-occipital activity, correlating with increased introspection and positive mood.

Published
December 1, 2016
Journal
Neuroscience and Biobehavioral Reviews
Authors
Dos Santos, R. G., Osório, F. L., Crippa, J. A., Hallak, J. E.

Clinical Trials

2 trials
CompletedPhase I

Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness

This double-blind, placebo-controlled, 6-period crossover study (n=16) evaluated escalating oral mescaline doses (100–800 mg) and ketanserin pre-treatment in healthy volunteers aged 25–65.

Started
January 5, 2021
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04849013
CompletedPhase I

Comparative Acute Effects of LSD, Psilocybin and Mescaline

This double-blind, placebo-controlled, 4-period crossover study (n≈32) compared single doses of LSD 100 µg, psilocybin 20 mg, mescaline 300/500 mg and placebo in healthy volunteers to characterise acute subjective, physiological and neural effects.

Started
May 19, 2020
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04227756

Explore further

Search all Mescaline papers Search all Neuroimaging & Brain Measures trials Full Mescaline profile Full Neuroimaging & Brain Measures profile